A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer - Concepedia

Concepedia

Publication | Open Access

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

DOI Full Paper Access

851

Citations

29

References

2008

Year

J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David R. Spigel, John L. Marshall, Allen Lee Cohn, David McCollum, Philip J. Stella,

Journal of Clinical Oncology

Abstract

The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.

References

	Year	Citations

Page 1